FrancophonIA/ELRC3.0 huggingface dataset:
English: In reproductive toxicology studies, skeletal effects and a reduction in foetal growth were observed in the rat and rabbit at exposures of dulaglutide 11- to 44-fold higher than those proposed clinically, but no foetal malformations were observed.
Maltese: kienu osservati effetti skeletriċi u tnaqqis fit-tkabbir tal-fetu fil-far u fil-fenek f'espożizzjonii għal dulaglutide ta' 11 sa 44 darba aktar minn dawk proposti b'mod kliniku, iżda ma kienu osservati l-ebda formazzjonijiet ħżiena fil-fetu.
English: Packs of 2 and 4 pre-filled pens and multipack of 12 (3 packs of 4) pre-filled pens.
Maltese: Pakketti ta' 2 u 4 pinen mimlijin għal-lest u pakkett multiplu ta' 12-il pinna (3 pakketti ta' 4) mimlijin għal-lest.
English: Trulicity 0.75 mg solution for injection in pre-filled syringe Trulicity 1.5 mg solution for injection in pre-filled syringe dulaglutide
Maltese: Trulicity 0.75 mg soluzzjoni għall-injezzjoni f'siringa mimlija għal-lest Trulicity 1.5 mg soluzzjoni għall-injezzjoni f'siringa mimlija għal-lest
English: When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued.
Maltese: Meta Trulicity jiżdied ma' terapija diġà eżitenti b'metformin u/jew pioglitazone, id-doża attwali ta' metformin u/jew pioglitazone tista' titkompla.
English: The safety and efficacy of dulaglutide were evaluated in nine randomised, controlled, phase III trials involving 6,193 patients with type 2 diabetes.
Maltese: III fejn il-pazjenti ntgħażlu b'mod arbitrarju u kienu jinvolvu 6,193 pazjent b'dijabete tat-tip 2.
English: Dulaglutide also slows gastric emptying.
Maltese: Dulaglutide idewwem ukoll l-iżvojtar tal-istonku.
English: Breast-feeding
Maltese: TAS-SIRINGA
English: Combination therapy with metformin and pioglitazone In a placebo and active (exenatide twice daily) controlled study, both in combination with metformin and pioglitazone, Trulicity 1.5 mg and 0.75 mg demonstrated superiority for HbA1c reduction in comparison to placebo and exenatide, accompanied by a significantly a greater percentage of patients achieving HbA1c targets of < 7.0 % or ≤ 6.5 %
Maltese: Fi studju bi plaċebo u kkontrollat b'mod attiv (exenatide darbtejn kuljum), it-tnejn li huma flimkien ma' metformin u pioglitazone, Trulicity 1.5 mg u 0.75 mg urew superjorità għal tnaqqis fl-HbA1c meta mqabbla ma' plaċebo u ma' exenatide, akkumpanjat minn perċentwal akbar b'mod sinifikanti ta'
English: DISPOSAL OF SYRINGE
Maltese: Ostruzzjoni intestinali mhux mekkanika
English: One patient reported severe hypoglycaemia with Trulicity 0.75 mg in combination with SGLT2i therapy and none with Trulicity 1.5 mg or placebo.
Maltese: Pazjent wieħed irrapporta ipogliċemija severa bi Trulicity 0.75 mg flimkien ma' terapija b'SGLT2i u l-ebda ipogliċemija bi Trulicity 1.5 mg jew plaċebo.
English: Store in a refrigerator (2ºC - 8ºC).
Maltese: 6.4 Prekawzjonijiet speċjali għall-ħażna Aħżen fi friġġ (2ºC - 8ºC).
English: The incidence of documented symptomatic hypoglycaemia when dulaglutide 1.5 mg was used with sulphonylurea alone was 11.3% and the rate was 0.90 events/patient/year, and there were no episodes of severe hypoglycaemia.
Maltese: L-inċidenza ta' ipogliċemija sintomatika li ġiet iddokumentata meta dulaglutide 1.5 mg intuża flimkien ma' xi sulphonylurea waħdu kienet ta' 11.3 % u r-rata kienet ta' 0.90 każ/pazjent/sena u ma kien hemm ebda episodju ta'
English: Skin and subcutaneous tissue disorders
Maltese: SKANNJA DAN IL-KODIĊI BIEX TIBDA
English: Dulaglutide 0.75 mg once weekly (n=272)
Maltese: Dulaglutide 0.75 mg darba fil-ġimgħa (n=272)
English: The safety and efficacy of dulaglutide was also investigated in an active controlled study (liraglutide 1.8 mg daily) of 26 weeks duration, both in combination with metformin.
Maltese: Is-sigurtà u l-effikaċja ta' dulaglutide ġiet investigata wkoll fi studju kkontrollat b'mod attiv (liraglutide 1.8 mg kuljum) li dam sejjer 26 ġimgħa, it-tnejn li huma mogħtija flimkien ma' metformin.
English: 3 PRESS AND HOLD
Maltese: Pressjoni tad-demm
English: Dulaglutide 0.75 mg once weekly (n=293)
Maltese: Dulaglutide 0.75 mg darba fil-ġimgħa (n=293)
English: FRONT
Maltese: Komuni
English: assessed for HbA1c only ** p < 0.001 dulaglutide treatment group compared to placebo ## p < 0.001 dulaglutide treatment group compared to sitagliptin
Maltese: plaċebo, stmat għal HbA1c biss ** p < 0.001 grupp ta' kura ta' dulaglutide mqabbel ma' plaċebo
English: Dulaglutide 0.75 mg once weekly (n=302)
Maltese: Dulaglutide 0.75 mg darba fil-ġimgħa (n=302)
English: The incidences when dulaglutide 0.75 mg and 1.5 mg, respectively, were used in combination with prandial insulin were 85.3% and 80.0% and rates were 35.66 and 31.06 events/patient/year.
Maltese: 3% u 80.0% u r-rati kienu 35.66 u 31.06 każijiet/pazjent/sena.
English: With Trulicity 1.5 mg a significantly higher percentage of patients reached a target HbA1c of < 7.0 % or ≤ 6.5 % at 52 and 78 weeks compared to insulin glargine.
Maltese: ≤ 6.5 % fis-26 ġimgħa u < 7.0 % fit-52 ġimgħa milli bl-insulina glargine.
English: The severe hypoglycaemia event incidences were 0% and 0.7%, and rates were 0.00 and 0.01 events/patient/year for each dose, respectively.
Maltese: L-inċidenzi ta' każ ta' ipogliċemija qawwija kienu 0% u 0.7%, u r-rati kienu 0.00 u 0.01 każ/pazjent/sena għal kull doża rispettivament.
English: One patient reported severe hypoglycaemia with Trulicity 1.5 mg in combination with insulin glargine and none with placebo.
Maltese: Ir-rati ta' ipogliċemija sintomatika ddokumentati b'Trulicity 1.5 mg u insulina glargine kienu ta'
English: No cases of severe hypoglycaemia were observed
Maltese: Ilma għall-injezzjonijiet
English: EU/1/14/956/007 4 pre-filled pens
Maltese: EU/1/14/956/004
English: OTHER INFORMATION
Maltese: Informazzjoni Oħra
English: Nausea, diarrhoea, vomiting†, abdominal pain†
Maltese: rimettar†, uġigħ fl-addome†
English: No dosage adjustment is required in patients with mild, moderate or severe renal impairment (eGFR <90 to ≥15 mL/min/1.73m2).
Maltese: Ma huwa meħtieġ l-ebda aġġustament fid-doża f'pazjenti b'indeboliment tal-kliewi ħafif, moderat.jew sever (eGFR <90 sa ≥15-il mL/min/1.73m2).
English: Studies characterising the pharmacokinetics of dulaglutide in paediatric patients have not been performed.
Maltese: Ma sarux studji biex jikkaretterizzaw il-farmakokinetika ta' dulaglutide f'pazjenti pedjatriċi.
English: Pharmacokinetic analyses have demonstrated a statistically significant inverse relationship between body weight or body mass index (BMI) and dulaglutide exposure, although there was no clinically relevant impact of weight or BMI on glycaemic control.
Maltese: Analiżi ta' farmakokinetika wrew relazzjoni statistikament sinifikanti bil-maqlub bejn il-piż tal-ġisem jew l-indiċi tal-massa tal-ġisem (BMI - body mass index) u l-espożizzjoni għal dulaglutide, għalkemm ma kien hemm l-ebda impatt rilevanti b'mod kliniku tal-piż jew il-BMI fuq il-kontroll ġliċemiku.
English: Each pen contains one weekly dose of Trulicity (0.75 mg or 1.5 mg).
Maltese: Kull pinna fiha doża waħda ta' ġimgħa ta' Trulicity (0.75 mg jew 1.5 mg).
English: The initial insulin glargine doses in patients with HbA1c <8.0% were reduced by 20%.
Maltese: Il-linja bażi medjana ta' HbA1c kienet ta' 7.2 %.
English: Hypoglycaemia* (when used in combination with insulin, glimepiride, metformin† or metformin plus glimepiride)
Maltese: Ipogliċemija* (meta jintuża flimkien malinsulina, ma' glimepiride, ma'metformin† jew ma' metformin u glimepiride)
English: With Trulicity 1.5 mg, a significantly higher percentage of patients reached a target HbA1c of < 7.0 % and ≤ 6.5 % at 24 weeks compared to placebo.
Maltese: BiTrulicity 1.5 mg, kien hemm persentaġġ sinifikament ogħla ta' pazjenti li laħqu l-mira ta' HbA1c ta' < 7.0% u ≤ 6.5% wara 24 ġimgħa meta mqabbel ma' plaċebo.
English: Firenze (FI)
Maltese: ANNESS III
English: Treatment with Trulicity 1.5mg in combination with glimepiride resulted in a statistically significant reduction in HbA1c compared to placebo with glimepiride at 24 weeks.
Maltese: Il-kura biTrulicity 1.5mg flimkien ma' glimepiride irriżulta f'tnaqqis fl-HbA1c li kien statistikament sinifikanti meta mqabbel ma' plaċebo flimkien ma' glimepiride wara 24 ġimgħa.
English: Dulaglutide 0.75 mg once weekly (n=280)
Maltese: Dulaglutide 0.75 mg darba fil-ġimgħa (n=280)
English: Discontinuation due to an adverse event
Maltese: Disturbi ġenerali u kondizzjonijiet ta'
English: Following a first dose of 1 and 3 mg dulaglutide, paracetamol Cmax was reduced by 36 % and 50 %, respectively, and the median tmax occurred later (3 and 4 hours, respectively).
Maltese: 50 %, rispettivament, u l-medjan tat-tmax seħħ aktar tard (3 u 4 sigħat, rispettivament).
English: 2 pre-filled pens of 0.5 ml solution 4 pre-filled pens of 0.5 ml solution
Maltese: 4 siringi mimlijin għal-lest b'soluzzjoni ta' 0.5 ml.
English: Beta-cell function
Maltese: INFORMAZZJONI BIL-BRAILLE
English: Placebo (n=140) ‡‡ p < 0.001 for superiority of dulaglutide compared to placebo, with overall type I error controlled ** p < 0.001 for dulaglutide treatment group compared to placebo
Maltese: Plaċebo (n=140) ‡‡ p < 0.001 għas-superjorità ta' dulaglutide meta mqabbel ma' plaċebo, bl-iżball in ġenerali ta' tip
English: Dulaglutide 0.75 mg once weekly (n=270)
Maltese: Dulaglutide 0.75 mg darba fil-ġimgħa (n=270)
English: Treatment with Trulicity 1.5 mg and 0.75 mg resulted in a superior reduction in HbA1c compared to sitagliptin at 52 weeks, accompanied by a significantly greater proportion of patients achieving HbA1c targets of < 7.0 % and ≤ 6.5 %.
Maltese: Kura bi Trulicity 1.5 mg u 0.75 mg wasslet għal tnaqqis superjuri fl-HbA1c meta mqabbel ma' sitagliptin fit-52 ġimgħa, akkumpanjat minn proporzjon ikbar b'mod sinifikanti ta' pazjenti li kisbu miri ta' HbA1c ta' < 7.0 % u ≤ 6.5 %.
English: Trulicity is injected under the skin (subcutaneous injection) of your stomach area (abdomen) or upper leg (thigh).
Maltese: Trulicity huwa injettat taħt il-ġilda (injezzjoni subkutaneja) fiż-żona tal-istonku (l-addome) jew finnaħa ta' fuq tar-riġel (il-koxxa).
English: Table 2: Results of a 52 week active controlled monotherapy study with two doses of dulaglutide in comparison to metformin
Maltese: Tabella 2: Riżultati ta' studju ta' monoterapija ikkontrollat b'mod attiv ta' 52 ġimgħa b'żewġ dożi ta'
English: Pack sizes of 4 or multipacks of 12 (3 packs of 4) pre-filled syringes.
Maltese: Daqsijiet tal-pakketti ta' 4 jew pakketti multipli ta' 12 (3 pakketti ta' 4)-il siringa mimlijin għal-lest.
English: In the phase II and phase III clinical studies, systemic hypersensitivity events (e.g., urticaria, edema) were reported in 0.5 % of patients receiving dulaglutide.
Maltese: III, każijiet ta' sensittività eċċessiva sistemika (eż., urtikarja, edima) ġew irrappurtati f'0.5 % tal-pazjenti li kienu qed jieħdu dulaglutide.
English: Sitagliptin 100 mg once daily (n=315) †† multiplicity adjusted 1-sided p-value < 0.025, for superiority of dulaglutide compared to sitagliptin,
Maltese: †† valur p 1-sided aġġustat għall-multipliċità < 0.025, għal superjorità ta' dulaglutide mqabbel ma'
English: Sun
Maltese: MINN
English: Insulin glargine+ once daily (n=262) † multiplicity adjusted 1-sided p-value < 0.025, for noninferiority; †† multiplicity adjusted 1-sided p-value < 0.025, for superiority of dulaglutide to insulin glargine, assessed for HbA1c only # p < 0.05, ## p < 0.001 dulaglutide treatment group compared to insulin glargine + Insulin glargine doses were adjusted utilising an algorithm with a fasting plasma glucose target of
Maltese: †† valur p 1-sided aġġustat għall-multipliċità < 0.025, għal superjorità ta' dulaglutide mqabbel ma' insulina glargine, stmat għal HbA1c biss
English: Placebo (n=60) ‡‡ p < 0.001 for superiority of dulaglutide compared to placebo, with overall type I error controlled ** p < 0.001 for dulaglutide treatment group compared to placebo
Maltese: (overall type I error) ikkontrollat ** p < 0.001 għall-grupp ta' trattament ta' dulaglutide meta mqabbel ma' plaċebo
English: The rates of documented symptomatic hypoglycaemia with Trulicity 1.5 mg and 0.75 mg, and sitagliptin were 0.19, 0.18, and 0.17 episodes/patient/year, respectively.
Maltese: ## p < 0.001 grupp ta' kura ta' dulaglutide mqabbel ma' sitagliptin Ir-rati ta' ipogliċemija bis-sintomi ddokumentata bi Trulicity1.5 mg u 0.75 mg u sitagliptin kienu 0.19, 0.18, u 0.17 episodji/pazjent/sena, rispettivament.
English: INJECT
Maltese: TIKKETTAR
English: Dulaglutide 1.5 mg once weekly (n=304)
Maltese: Dulaglutide 1.5 mg darba fil ġimgħa(n=304)
English: In all studies, dulaglutide produced clinically significant improvements in glycaemic control as measured by glycosylated haemoglobin A1c (HbA1c).
Maltese: III ma wera l-ebda impatt ċar ta' antikorpi ta' kontra l-mediċina għal dulaglutide fuq tibdil fl-HbA1c.
English: - Hypoglycaemia (low blood sugar) is very common when dulaglutide is used with medicines that contain metformin, a sulphonylurea and/or insulin.
Maltese: - L-ipogliċemija (livell baxx ta' zokkor fid-demm) hija komuni ħafna meta dulaglutide jintuża ma' mediċini li fihom metformin, xi sulphonylurea u/jew insulina.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Trulicity 0.75 mg solution for injection Each pre-filled syringe contains 0.75 mg of dulaglutide* in 0.5 ml solution.
Maltese: - Trulicity 0.75 mg: Kull siringa mimlija għal-lest fiha 0.75 mg ta' dulglutide f'0.5 ml ta' soluzzjoni.
English: Sitagliptin 100 mg once daily (n=315) †† multiplicity adjusted 1-sided p-value < 0.025, for superiority of dulaglutide compared to sitagliptin, assessed only for HbA1c at 52 and 104 weeks ‡‡ multiplicity adjusted 1-sided p-value < 0.001 for superiority of dulaglutide compared to placebo,
Maltese: sitagliptin, stmat għal HbA1c biss fit-52 ġimgħa u fil-104 ġimgħat ‡‡ valur p 1-sided aġġustat għall-multipliċità < 0.001, għal superjorità ta' dulaglutide mqabbel ma'
English: IMMUNOSUPPRESSIVES Cyclosporine A
Maltese: IMMUNOSUPPRESSIVI Cyclosporine A
English: Midazolam (parenteral)
Maltese: Midazolam (parenterali)
English: • The active substance is indinavir.
Maltese: • Is-sustanza attiva hi indinavir.
English: *)historical controls
Maltese: (*)kontrolli storiċi
English: STEROIDS Dexamethasone
Maltese: STEROJDI Dexamethasone
English: Anhydrous lactose.
Maltese: TA' EĊĊIPJENTI Anhydrous lactose.
English: Indinavir did not significantly inhibit the eukaryotic proteases human renin, human cathepsin D, human elastase, and human factor Xa.
Maltese: Indinavir ma' jinibixxix b'mod sinifikanti eukaryotic proteases human renin, human cathepsin D, human elastase, u human factor Xa.
English: 2031 BN Haarlem The Netherlands
Maltese: 2031 BN Haarlem, In-Netherlands
English: IMMUNOSUPPRESSIVES Cyclosporine A (Indinavir/ritonavir 800/100 BID)
Maltese: IMMUNOSUPPRESSIVI Cyclosporine A (Indinavir/ritonavir 800/100
English: SEDATIVES/HYPNOTICS Midazolam (parenteral)
Maltese: SEDATTIVI/IPNOTIĊI Midazolam (parenterali)
English: PDE5 INHIBITOR Sildenafil, tadalafil
Maltese: INIBITUR PDE5 Sildenafil, tadalafil
English: At least eleven amino acid sites in the protease have been associated with indinavir resistance: L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, and L90.
Maltese: Hemm mill-inqas ħdax-il sit ta' l-amino aċidi fil-protease li ġew marbuta mar-reżistenza lil indinavir : L10, K20, L24, M46, I54, L63, I64, A71, V82, I84, u L90.
English: Box 581, 2003 PC Haarlem, The Netherlands
Maltese: Box 581, 2003 PC
English: haematuria, proteinuria, crystalluria nephrolithiasis, dysuria.
Maltese: ematurja, proteinurja, kristallurja nefrolitjasi, disurja.
English: Cyclosporine A (CsA) levels markedly increase in patients on PIs, including indinavir.
Maltese: Livelli ta' Cyclosporine A (CsA) jiżdiedu sostanzjalment f'pazjenti fuq PIs, inkluż indinavir.
English: Indinavir AUC:  11 % Sildenafil AUC  340 %
Maltese: AUC Indinavir:  11% AUC Sildenafil  340%
English: Formulation with buffer
Maltese: Formulazzjoni b'buffer
English: • sildenafil, vardenafil, tadalafil - used for impotence
Maltese: • sildenafil, vardenafil, tadalafil - jintużaw għall-impotenza
English: • delavirdine, efavirenz, nevirapine - used for HIV
Maltese: • delavirdine, efavirenz, nevirapine - jintużaw għall-HIV
English: Norethindrone AUC: ↑ 26 % Norethindrone Cmin: ↑ 44 %
Maltese: AUC Norethindrone: ↑ 26% Cmin Norethindrone: ↑ 44%
English: Corresponding plasma concentrations at 8 hours post dose were 220 nM, 210 nM and 370 nM, respectively.
Maltese: Il-konċentrazzjonijiet korrispondenti tal-plażma 8 sigħat wara d-dożi kienu 220 nM, 210 nM u 370 nM, rispettivament.
English: Lamivudine AUC:  Lamivudine Cmin: 
Maltese: AUC Lamivudine:  Cmin Lamivudine: 
English: ANTICONVULSANTS Carbamazepine, phenobarbital phenytoin
Maltese: Carbamazepine, phenobarbital phenytoin
English: • venlafaxine, trazodone - used for depression
Maltese: • venlafaxine, trazodone - jintużaw għad-depressjoni
English: Medicinal product interactions
Maltese: Interazzjonjiet ta' prodotti mediċinali
English: • allergies
Maltese: • allerġiji
English: 180 hard capsules 270 hard capsules 360 hard capsules
Maltese: 180 kapsula iebsa 270 kapsula iebsa 360 kapsula iebsa
English: CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV-1 infected adults.
Maltese: CRIXIVAN huwa indikat flimkien ma' antiretroviral nucleoside analogues għat-trattament ta' adulti infettati bl-HIV-1.
English: Other substitutions were observed less frequently.
Maltese: Sostituzzjonijiet oħra ġew osservati b'mod inqas frekwenti.
English: Manufacturer: Merck Sharp & Dohme B.V., Waarderweg 39, Postbus 581, 2003 PC Haarlem The Netherlands
Maltese: Merck Sharp & Dohme B.V., Waarderweg 39, Postbus 581, 2003 PC
English: Excipient with known effect Each 400 mg capsule contains 149.6 mg of lactose.
Maltese: Kull kapsula ta' 400 mg fiha 149.6 mg ta' lactose.
English: • amprenavir, saquinavir, atazanavir - used for HIV
Maltese: • amprenavir, saquinavir, atazanavir - jintużaw għall-HIV
English: NNRTIs
Maltese: NRTIs
English: These adverse reactions were: nausea (35.3 %), headache (25.2 %), diarrhoea (24.6 %), asthenia/fatigue (24.3 %), rash (19.1 %), taste perversion (19.1 %), dry skin (16.2 %), abdominal pain (14.6 %), vomiting (11.0 %), dizziness (10.7 %).
Maltese: Dawn ir-reazzjonijiet avversi kienu: tqalligħ (35.3 %), uġigħ ta' ras (25.2 %), dijarea (24.6 %), astenja/għeja (24.3 %), raxx (19.1 %), perverżjoni tat-togħma (19.1 %), ġilda xotta (16.2 %), uġigħ addominali (14.6 %), rimettar (11.0 %), sturdament (10.7 %).
English: Tel.: +420 233 010 111 dpoc_czechslovak@merck.com
Maltese: +420 233 010 111 dpoc_czechslovak@merck.com
English: Do not take CRIXIVAN:
Maltese: Tiħux CRIXIVAN:
English: is ritonavir.
Maltese: ma' ritonavir.
English: ORAL CONTRACEPTIVES Norethindrone/ethinyl estradiol 1/35 1 mcg QD (Indinavir 800 mg TID)
Maltese: Norethindrone/ethinyl estradiol 1/35 1 mcg QD (Indinavir 800 mg TID)
English: ANTIDEPRESSANTS Trazodone 50 mg SD Ritonavir 200 mg BID
Maltese: Trazodone 50 mg SD Ritonavir 200 mg BID
English: This is called combination antiretroviral therapy.
Maltese: Din tissejjaħ terapija antiretrovirali kkombinata.
English: Zidovudine AUC:  Zidovudine Cmin: ↑ 51 %
Maltese: Cmin Zidovudine: ↑ 51%
English: Very common (≥ 1/10); Common (≥ 1/100 to  1/10); Uncommon (≥ 1/1,000 to < 1/100);
Maltese: Komuni ħafna (≥ 1/10); Komuni (≥ 1/100 sa < 1/10);
English: Excipient with known effect Each 200 mg capsule contains 74.8 mg lactose.
Maltese: Kull kapsula ta' 200 mg fiha 74.8 mg ta' lactose.
English: • phenobarbital, phenytoin, carbamazepine, divalproex, lamotrigine - medicines used to treat fits (epilepsy)
Maltese: • phenobarbital, phenytoin, carbamazepine, divalproex, lamotrigine - mediċini li jintużaw biex jikkuraw aċċessjonijiet (epilessija)
English: HERBAL MEDICATIONS St. John's wort (Hypericum perforatum) 300 mg TID (Indinavir 800 mg TID)
Maltese: John's wort (Hypericum perforatum) 300 mg TID (Indinavir 800 mg TID)
English: CD4 cells are an important part of your immune system.
Maltese: Iċ-ċelluli CD4 huma parti importanti mis-sistema immuni tiegħek.
English: Other Anti-infectives Atovaquone
Maltese: Anti-infettivi oħrajn Atovaquone
English: ANALGESICS Fentanyl
Maltese: ANALĠESIĊI Fentanyl
English: HIV Transmission
Maltese: Trasmissjoni tal-HIV
English: ANTIARRHYTHMICS Quinidine 200 mg SD (Indinavir 400 mg SD)
Maltese: ANTIARRITMIĊI Quinidine 200 mg SD (Indinavir 400 mg SD)
English: Indinavir AUC:  28 % Nevirapine:  (CYP3A induction)
Maltese: AUC Indinavir:  28 % Nevirapine:  (Induzzjoni
English: Osteonecrosis:
Maltese: Ostejonekrożi:
English: Indinavir AUC: 
Maltese: AUC Indinavir:
English: • morphine, fentanyl - used for pain
Maltese: • morphine, fentanyl - jintużaw għall-uġigħ
English: Amlodipine 5 mg QD (Indinavir/ritonavir 800/100 BID)
Maltese: Amlodipine 5 mg QD (Indinavir/ritonavir 800/100
English: Rifabutin AUC*: ↑ 54 % Rifabutin Cmin*: ↑ 99 % (*Relative to rifabutin 300 mg QD alone.
Maltese: AUC Rifabutin *: ↑ 54% Cmin Rifabutin *: ↑ 99% (*Għal rifabutin 300 mg QD waħdu.
English: The pharmacokinetic parameters in the second study were comparable.
Maltese: Il parametri farmakokinetiċi fit-tieni studju kienu komparabbli.
English: Atazanavir as well as indinavir are associated with indirect (unconjugated) hyperbilirubinemia due to inhibition of UDP-glucuronosyltransferase (UGT).
Maltese: Atazanavir kif ukoll indinavir huma assoċjati ma' iperbilirubinimja indiretta (mhux konjugata) minħabba l-inibizzjoni ta' UDP-glucuronosyltransferase (UGT).
English: Amprenavir 1,200 mg BID AUC ↑90 % with 800 mg TID indinavir alone (see Table 1).
Maltese: AUC Amprenavir BID 1200 mg ↑90% b'800 mg TID indinavir waħdu (ara Tabella 1).
English: Indinavir AUC ↓ 34 %
Maltese: AUC Indinavir ↓ 56%
English: EU/1/96/024/004 EU/1/96/024/005
Maltese: EU/1/96/024/005
English: The mean half-life of indinavir increased to approximately 2.8 hours.
Maltese: Il-half life ta' indinavir jitwal bejn wieħed u ieħor għal 2.8 sigħat.
English: Indinavir at concentrations of 50 to 100 nM mediated 95 % inhibition (IC95) of viral spread (relative to an untreated virus-infected control) in human T-lymphoid cell cultures and primary human monocytes/macrophages infected with HIV 1 variants LAI, MN, RF, and a macrophage-tropic variant SF-162, respectively.
Maltese: Indinavir f'konċentrazzjonjiet ta' minn 50 sa 100 nM immedja 95 % ta' l-inibizzjoni (IC95) tal-firxa virali (meta mqabbel mal-kontroll mhux ikkurat infettat bil-virus) f'kulturi ċellulari tat-T-limfojd umani u monoċiti u makrofaġi umani infettati bil-varjanti ta' l-HIV-1 LAI, MN, RF, u varjant makrofagu-tropiku SF-162, rispettivament.
English: • lower the risk that you get illnesses related to HIV
Maltese: • inaqqas ir-riskju li inti jaqbdek mard marbut mal-HIV
English: For the full list of excipients, see section 6.1
Maltese: Għal-lista kompluta ta' eċċipjenti, ara sezzjoni 6.1
English: Midazolam is extensively metabolized by CYP3A4.
Maltese: Midazolam huwa metabolizzat b'mod estensiv minn CYP3A4.
English: The bioavailability of a single 800-mg dose of indinavir was approximately 65 % (90 % CI, 58 - 72 %).
Maltese: Il-biodisponibbilita` ta' doża waħda ta' 800mg ta' indinavir kienet bejn wieħed u ieħor ta' 65 % (90 % CI, 58 - 72 %).
English: Amprenavir AUC: ↑ 90 % Indinavir: ↔
Maltese: AUC Amprenavir: ↑ 90%
English: Interaction with indinavir/ritonavir not studied R-warfarin levels may be decreased leading to reduced anticoagulation due to induction of CYP1A2 and CYP2C9 by ritonavir.
Maltese: Il-livelli ta' R-warfarin jistgħu jitnaqqsu u jwasslu għal antikoagulazzjoni mnaqqsa minħabba induzzjoni ta' CYP1A2 u CYP2C9
English: Rifabutin AUC: ↑ 173 % Rifabutin Cmin: ↑ 244 % (Relative to rifabutin 300 mg QD alone)
Maltese: AUC Rifabutin: ↑ 173% Cmin Rifabutin: ↑ 244% (Għal rifabutin 300 mg QD waħdu)
English: The metabolism of indinavir is mediated by the cytochrome P450 enzyme CYP3A4.
Maltese: Il-metaboliżmu ta' indinavir jsir permezz ta' l-enzima CYP3A4 cytochrome P450.
English: • raise your CD4 (T) cell count.
Maltese: • jgħolli l-għadd ta' ċelluli CD4 (T) tiegħek.
English: ANTIASTHMATIC Theophylline 250 mg SD (Indinavir 800 mg TID)
Maltese: ANTIAŻŻMATIĊI Theophylline 250 mg SD (Indinavir 800 mg TID)